Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 37


Adjuvant Therapy Trials.

Ursem C, Van Loon K, Venook A.

Cancer J. 2016 May-Jun;22(3):196-198.


Non-Invasive Continuous Respiratory Monitoring on General Hospital Wards: A Systematic Review.

van Loon K, van Zaane B, Bosch EJ, Kalkman CJ, Peelen LM.

PLoS One. 2015 Dec 14;10(12):e0144626. doi: 10.1371/journal.pone.0144626. eCollection 2015.


A Phase I First-in-Human Study of Nesvacumab (REGN910), a Fully Human Anti-Angiopoietin-2 (Ang2) Monoclonal Antibody, in Patients with Advanced Solid Tumors.

Papadopoulos KP, Kelley RK, Tolcher AW, Razak AR, Van Loon K, Patnaik A, Bedard PL, Alfaro AA, Beeram M, Adriaens L, Brownstein CM, Lowy I, Kostic A, Trail PA, Gao B, DiCioccio AT, Siu LL.

Clin Cancer Res. 2016 Mar 15;22(6):1348-55. doi: 10.1158/1078-0432.CCR-15-1221. Epub 2015 Oct 21.


Wireless non-invasive continuous respiratory monitoring with FMCW radar: a clinical validation study.

van Loon K, Breteler MJ, van Wolfwinkel L, Rheineck Leyssius AT, Kossen S, Kalkman CJ, van Zaane B, Peelen LM.

J Clin Monit Comput. 2015 Sep 30. [Epub ahead of print]


Barriers and facilitators perceived by physicians when using prediction models in practice.

Kappen TH, van Loon K, Kappen MA, van Wolfswinkel L, Vergouwe Y, van Klei WA, Moons KG, Kalkman CJ.

J Clin Epidemiol. 2016 Feb;70:136-45. doi: 10.1016/j.jclinepi.2015.09.008. Epub 2015 Sep 21.


Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary Carcinomas.

Zill OA, Greene C, Sebisanovic D, Siew LM, Leng J, Vu M, Hendifar AE, Wang Z, Atreya CE, Kelley RK, Van Loon K, Ko AH, Tempero MA, Bivona TG, Munster PN, Talasaz A, Collisson EA.

Cancer Discov. 2015 Oct;5(10):1040-8. doi: 10.1158/2159-8290.CD-15-0274. Epub 2015 Jun 24.


The incidence of oesophageal cancer in Eastern Africa: identification of a new geographic hot spot?

Cheng ML, Zhang L, Borok M, Chokunonga E, Dzamamala C, Korir A, Wabinga HR, Hiatt RA, Parkin DM, Van Loon K.

Cancer Epidemiol. 2015 Apr;39(2):143-9. doi: 10.1016/j.canep.2015.01.001. Epub 2015 Feb 3.


Bone metastases and skeletal-related events from neuroendocrine tumors.

Van Loon K, Zhang L, Keiser J, Carrasco C, Glass K, Ramirez MT, Bobiak S, Nakakura EK, Venook AP, Shah MH, Bergsland EK.

Endocr Connect. 2015 Mar;4(1):9-17. doi: 10.1530/EC-14-0119. Epub 2014 Nov 27.


Cultural diversity: blind spot in medical curriculum documents, a document analysis.

Paternotte E, Fokkema JP, van Loon KA, van Dulmen S, Scheele F.

BMC Med Educ. 2014 Aug 22;14:176. doi: 10.1186/1472-6920-14-176.


25-Hydroxyvitamin D levels and survival in advanced pancreatic cancer: findings from CALGB 80303 (Alliance).

Van Loon K, Owzar K, Jiang C, Kindler HL, Mulcahy MF, Niedzwiecki D, O'Reilly EM, Fuchs C, Innocenti F, Venook AP; Alliance for Clinical Trials in Oncology.

J Natl Cancer Inst. 2014 Aug 6;106(8). pii: dju185. doi: 10.1093/jnci/dju185. Print 2014 Aug.


Treatment-related Hypertension as a Pharmacodynamic Biomarker for the Efficacy of Bevacizumab in Advanced Pancreas Cancer: A Pooled Analysis of 4 Prospective Trials of Gemcitabine-based Therapy With Bevacizumab.

Pant S, Martin LK, Geyer S, Wei L, Van Loon K, Sommovilla N, Zalupski M, Iyer R, Fogelman D, Ko AH, Bekaii-Saab T.

Am J Clin Oncol. 2014 Jul 25. [Epub ahead of print]


Capnography during deep sedation with propofol by nonanesthesiologists: a randomized controlled trial.

van Loon K, van Rheineck Leyssius AT, van Zaane B, Denteneer M, Kalkman CJ.

Anesth Analg. 2014 Jul;119(1):49-55. doi: 10.1213/ANE.0b013e3182a1f0a2.


Experiences with EPAs, potential benefits and pitfalls.

van Loon KA, Driessen EW, Teunissen PW, Scheele F.

Med Teach. 2014 Aug;36(8):698-702. doi: 10.3109/0142159X.2014.909588. Epub 2014 May 7.


Baseline serum albumin is a predictive biomarker for patients with advanced pancreatic cancer treated with bevacizumab: a pooled analysis of 7 prospective trials of gemcitabine-based therapy with or without bevacizumab.

Pant S, Martin LK, Geyer S, Wei L, Van Loon K, Sommovilla N, Zalupski M, Iyer R, Fogelman D, Ko AH, Bekaii-Saab T.

Cancer. 2014 Jun 15;120(12):1780-6. doi: 10.1002/cncr.28648. Epub 2014 Mar 13. Erratum in: Cancer. 2015 Apr 1;121(7):1154.


Should combination chemotherapy serve as the backbone in clinical trials of advanced pancreatic cancer? A pooled analysis of phase II trials of gemcitabine-containing doublets plus bevacizumab.

Van Loon K, Espinoza AM, Fogelman DR, Wolff RA, Javle MM, Iyer RV, Picozzi VJ, Martin LK, Bekaii-Saab T, Tempero MA, Foster NR, Kim GP, Ko AH.

Pancreas. 2014 Apr;43(3):343-9. doi: 10.1097/MPA.0000000000000095.


Curable patient with metastatic colorectal cancer: balancing effective therapies and toxicities.

Van Loon K, Venook AP.

J Clin Oncol. 2014 Apr 1;32(10):991-6. doi: 10.1200/JCO.2013.53.5195. Epub 2014 Feb 10. No abstract available.


Biomarkers in colon cancer: the chasm between expectations and reality.

Van Loon K, Venook AP.

Oncology (Williston Park). 2013 Aug;27(8):758, 763. No abstract available.


Comparison of dietary and lifestyle habits among stage III and metastatic colorectal cancer patients: findings from CALGB 89803 and CALGB 80405.

Van Loon K, Wigler D, Niedzwiecki D, Venook AP, Fuchs C, Blanke C, Saltz L, Goldberg RM, Meyerhardt JA.

Clin Colorectal Cancer. 2013 Jun;12(2):95-102. doi: 10.1016/j.clcc.2012.11.002. Epub 2013 Jan 12.


Counterpoint: Adjuvant therapy in stage II colon cancer: pain not justified by the gain.

Van Loon K, Venook AP.

J Natl Compr Canc Netw. 2012 Nov 1;10(11):1379-86.


Metastatic colorectal cancer: a curable disease.

Van Loon K, Venook AP.

Oncology (Williston Park). 2012 Mar;26(3):275-6, 282. No abstract available.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk